AbbVie ABBV Stock
AbbVie Price Chart
AbbVie ABBV Financial and Trading Overview
| AbbVie stock price | 217.13 USD |
| Previous Close | 217.72 USD |
| Open | 215.26 USD |
| Bid | 211.78 USD x 20000 |
| Ask | 211.9 USD x 10000 |
| Day's Range | 211.51 - 216.5 USD |
| 52 Week Range | 181.73 - 244.81 USD |
| Volume | 1.99M USD |
| Avg. Volume | 6.69M USD |
| Market Cap | 375.62B USD |
| Beta (5Y Monthly) | 0.305 |
| PE Ratio (TTM) | 103.70732 |
| EPS (TTM) | 2.04 USD |
| Forward Dividend & Yield | 6.92 (3.18%) |
| Ex-Dividend Date | April 15, 2026 |
| 1y Target Est | 252.9 USD |
ABBV Valuation Measures
| Enterprise Value | 448.23B USD |
| Trailing P/E | 103.70732 |
| Forward P/E | 13.099384 |
| PEG Ratio (5 yr expected) | 0.6 |
| Price/Sales (ttm) | 5.979404 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 7.135 |
| Enterprise Value/EBITDA | 14.983 |
Trading Information
AbbVie Stock Price History
| Beta (5Y Monthly) | 0.305 |
| 52-Week Change | 16.43% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 244.81 USD |
| 52 Week Low | 181.73 USD |
| 50-Day Moving Average | 208.23 USD |
| 200-Day Moving Average | 219.59 USD |
ABBV Share Statistics
| Avg. Volume (3 month) | 6.69M USD |
| Avg. Daily Volume (10-Days) | 5.42M USD |
| Shares Outstanding | 1.77B |
| Float | 1.76B |
| Short Ratio | 3.39 |
| % Held by Insiders | 0.11% |
| % Held by Institutions | 76.85% |
| Shares Short | 22.59M |
| Short % of Float | 1.41% |
| Short % of Shares Outstanding | 1.28% |
Dividends & Splits
| Trailing Annual Dividend Rate | 6.74 |
| Trailing Annual Dividend Yield | 3.09% |
| 5 Year Average Dividend Yield | 360.00% |
| Payout Ratio | 3.2598002 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 5.78% |
| Operating Margin (ttm) | 32.15% |
| Gross Margin | 72.02% |
| EBITDA Margin | 47.62% |
Management Effectiveness
| Return on Assets (ttm) | 10.03% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 62.82B USD |
| Revenue Per Share (ttm) | 35.5 USD |
| Quarterly Revenue Growth (yoy) | 12.40% |
| Gross Profit (ttm) | 45.25B USD |
| EBITDA | 29.92B USD |
| Net Income Avi to Common (ttm) | 3.6B USD |
| Diluted EPS (ttm) | 2.05 |
| Quarterly Earnings Growth (yoy) | -46.00000000000000000000000000000000% |
Balance Sheet
| Total Cash (mrq) | 9.39B USD |
| Total Cash Per Share (mrq) | 5.32 USD |
| Total Debt (mrq) | 72.91B USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.796 |
| Book Value Per Share (mrq) | -3.767 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 21.22B USD |
| Levered Free Cash Flow (ttm) | 20.81B USD |
Profile of AbbVie
| Country | United States |
| State | IL |
| City | North Chicago |
| Address | 1 North Waukegan Road |
| ZIP | 60064-6400 |
| Phone | 847 932 7900 |
| Website | https://www.abbvie.com |
| Industry | Drug Manufacturers - General |
| Sector(s) | Healthcare |
| Full Time Employees | 57000 |
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Q&A For AbbVie Stock
What is a current ABBV stock price?
AbbVie ABBV stock price today per share is 217.13 USD.
How to purchase AbbVie stock?
You can buy ABBV shares on the NYSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for AbbVie?
The stock symbol or ticker of AbbVie is ABBV.
Which industry does the AbbVie company belong to?
The AbbVie industry is Drug Manufacturers - General.
How many shares does AbbVie have in circulation?
The max supply of AbbVie shares is 1.77B.
What is AbbVie Price to Earnings Ratio (PE Ratio)?
AbbVie PE Ratio is 106.43628000 now.
What was AbbVie earnings per share over the trailing 12 months (TTM)?
AbbVie EPS is 2.04 USD over the trailing 12 months.
Which sector does the AbbVie company belong to?
The AbbVie sector is Healthcare.
AbbVie ABBV included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| S&P 500 INDEX SPX | 7553.68 USD — |
-0.74
|
3.46B USD — | — — | — — | — - | 3.46B USD — |
| S&P 500 (Yahoo.com) GSPC | 7553.68 USD — |
-0.74
|
3.41B USD — | 7551.22 USD — | 7605.35 USD — | — - | 3.41B USD — |
| S&P 100 SP100 | 3744.08 USD — |
-0.93
|
1.6B USD — | 3741.59 USD — | 3781.27 USD — | — - | 1.6B USD — |
| Dow Jones U.S. Biotechnology In DJUSBT | 2955.74 USD — |
+1.36
|
86.46M USD — | 2895.27 USD — | 2961.37 USD — | — - | 86.46M USD — |
| US Tech DM Ex Japan Large Mid Ca NQDMXJPLMAUD | 2100.38 AUD 1390.15 USD |
<0.01
|
— — | 2100.38 AUD 1390.15 USD | 2100.38 AUD 1390.15 USD | — - | — — |
| The Capital Strength Net Total NQCAPSTN | 4020.13 USD — |
-0.05
|
— — | 4011.24 USD — | 4033.31 USD — | — - | — — |
| NYSE Arca Pharmaceutical Index DRG | 1127.15 USD — |
+0.32
|
— — | — — | — — | — - | — — |
| US Tech US Smart Pharmaceuticals NQSSPH | 1832.72 USD — |
+1.64
|
— — | 1800.06 USD — | 1835.39 USD — | — - | — — |
| US Tech AlphaDEX Multi Cap Growt NQDXUSMLTCG | 4054.02 USD — |
-0.25
|
— — | 4019.75 USD — | 4077 USD — | — - | — — |
| US Tech CRD Global Sustainabilit NQCRD | 1735.62 USD — |
0
|
— — | 1715.94 USD — | 1757.95 USD — | — - | — — |
| The Capital Strength Index NQCAPST | 3368.83 USD — |
-0.05
|
— — | 3361.59 USD — | 3379.89 USD — | — - | — — |
| Dorsey Wright Momentum Plus Div DWAMY | 1758.05 USD — |
-0.28
|
— — | 1758.05 USD — | 1758.05 USD — | — - | — — |
| NYSE Composite Index NYA | 23276.49 USD — |
-0.87
|
— — | — — | — — | — - | — — |
| US Tech US Price Setters Index NQPRCE | 2899.6 USD — |
-0.61
|
— — | 2899.37 USD — | 2909.46 USD — | — - | — — |
- {{ link.label }} {{link}}